公司資料
Veracyte 股價、新聞與催化劑
- 股票代碼:
- VCYT
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
45.81 USD (+3.67%)
收盤價
最後更新: 2026年10月2日
3.81B USD
市值
股價為何變動
截至 2026年10月2日，VCYT 上漲 3.67%，收於 $45.81。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Cancer Diagnostics Company
Veracyte develops molecular tests that analyze tumor biology to support diagnosis, prognosis, treatment selection, and disease monitoring across multiple cancer types.
Decipher Urologic Diagnostics
The Decipher franchise includes genomic classifiers for prostate and bladder cancer. These tests help clinicians assess disease aggressiveness and inform treatment intensity at key decision points.
Afirma Thyroid Testing
Afirma evaluates indeterminate thyroid nodules to help determine which patients may avoid diagnostic surgery and which may require further intervention. The platform also generates molecular information that can support treatment planning.
Breast and MRD Expansion
Prosigna estimates recurrence risk in early-stage hormone-receptor-positive breast cancer, while TrueMRD uses whole-genome sequencing to monitor molecular residual disease, initially in muscle-invasive bladder cancer.
Integrated Diagnostics Platform
Veracyte combines genomic and clinical data, bioinformatics, AI, laboratory operations, and evidence generation. The portfolio also includes programs in lung cancer and interstitial lung disease, creating opportunities across the diagnostic and treatment continuum.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。